Jacobio Pharma Present Data: BET Inhibitor for Myelofibrosis
December 9, 2024
Jacobio Pharma, a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat